{
    "clinical_study": {
        "@rank": "77098", 
        "arm_group": [
            {
                "arm_group_label": "Korean traditional diets", 
                "arm_group_type": "Experimental", 
                "description": "Korean traditional diets (calorie 2,100kcal) for 12weeks"
            }, 
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "Active Comparator", 
                "description": "Control group : told to \"eat as usal diet) for 12weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is being conducted to look for following changes when Korean traditional diets is\n      taken in subjects with hypertension and type 2 diabetes:\n\n      To evaluate the improvement of the controlling fasting blood glucose  and glycated\n      hemoglobin.\n\n      To assess the controlling blood pressure and heart rate.\n\n      To evaluate the influence on cardiovascular risk factor, Triglyceride, cholesterol, High\n      Density Lipoprotein-cholesterol and Low-Density Lipoprotein-cholesterol.\n\n      To evaluate the influence on Gamma-Glutamyl Transpeptidase.\n\n      To evaluate the influence on Cardiovascular risk factor.\n\n      To evaluate the influence on valsava score, breathing score and upright score."
        }, 
        "brief_title": "Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes", 
        "completion_date": {
            "#text": "February 2011", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus, Type 2", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators aimed to investigate the efficacy of Korean traditional diets in\n      controlling fasting blood glucose fluctuation, blood pressure, and cardiovascular risk\n      factors in hypertensive and type 2 diabetic patients who were taking medications prescribed\n      for respective diseases in a 12-week."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who are men and women volunteers 19~80years\n\n          -  Subject who have hypertension and type 2diabetes.\n\n          -  Subject who have taking oral medications :\n\n        (hypoglycemic, blood pressure and lipid modifying drugs).\n\n          -  Subject must provide written informed consent to participate in the study.\n\n        Exclusion Criteria:\n\n          -  Subject with a history or evidence of clinically significant\n             gastrointestinal,anorectal, hepatic, renal, neurological, pulmonary, endocrine, blood\n             tumor,psychiatric.\n\n          -  Hypertension(DBP>116mmHg or SBP>200 mmHg) having the history of   cardiovascular\n             events or taking medications known to affect lipoprotein      metabolism.\n\n          -  Having Type 1 diabetes mellitus or uncontrolled Type 2 diabetes mellitus   (HbA1c\n             >9.0%).\n\n          -  Subjects with the history of cancer.\n\n          -  Subjects who have a gastrointestinal (GI) disease (Crohn's disease, etc.) that would\n             increase the influence with absorbance medication or a GI surgery   excluding\n             appendectomy and hernia surgery.\n\n          -  Having digestive, or central nervous system disorders.\n\n          -  Subject is  hematologic, or neuroretinopathy.\n\n          -  Subject with uterine fibroids at ultrasonography.\n\n          -  Having severe or malignant retinopathy.\n\n          -  Having the impairment of renal and liver function, dysproteinemia, nephritic\n             syndrome, or other renal disease.\n\n          -  Having coagulopathy\n\n          -  Having human immunodeficiency virus.\n\n          -  Having the history of mental instability and of drug and alcohol.\n\n          -  Having the history of reactions to our experimental products.\n\n          -  Participating in other clinical trials within the past 2 months.\n\n          -  Having laboratory tests, medical or psychological conditions deemed by   the\n             investigators to interfere with successful participation in the study.\n\n          -  Having the history of alcohol or substance abuse.\n\n          -  Subject is pregnant, planning to become pregnant, or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724645", 
            "org_study_id": "CUH_KOREAN-FOOD_2-2_2010"
        }, 
        "intervention": [
            {
                "arm_group_label": "Korean traditional diets", 
                "description": "The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.\nThe Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods.", 
                "intervention_name": "Korean traditional diets", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "The Korean Traditonal diets"
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "Told to \" eat as usal diets\".", 
                "intervention_name": "Control group", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Control diets"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Korean Traditional diets", 
            "hypertension", 
            "diabetes"
        ], 
        "lastchanged_date": "November 9, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jeonju", 
                    "country": "Korea, Republic of", 
                    "state": "Jeollabuk-do", 
                    "zip": "560-822"
                }, 
                "name": "Clinical Trial Center for Functional Foods; Chonbuk National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Open Label, Parallel Controlled, to Evaluate the Beneficial Effects of Korean Traditional Dites in Subjects With Hypertension and Type 2 Diabetes.", 
        "other_outcome": [
            {
                "description": "weight is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "weight", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "BMI is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "BMI:Body Mass Index", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Body fat percent is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "Body fat percent", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Waist is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "Waist", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Bacteriodetes is measured in study visits to the clinic, week 0(baseline)and week 12.", 
                "measure": "Obesity associated gut microbiome(Bacteriodetes)", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Firmicutes is measured in study visits to the clinic, week 0(baseline)and week 12.", 
                "measure": "Obesity associated gut microbiome(Firmicutes)", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Hypoglycemic oral medication is measured in study 0wk, 4wk, 8wk and 12wk.", 
                "measure": "Hypoglycemic(oral medication)", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Control blood pressure(oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.", 
                "measure": "Control blood pressure(oral medication)", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Lipid modifying (oral medication) is measured in study 0wk, 4wk, 8wk and 12wk.", 
                "measure": "Lipid modifying (oral medication)", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }
        ], 
        "overall_official": {
            "affiliation": "Chonbuk National University Hospital", 
            "last_name": "Soo-Wan Chae, MD., PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Glycated Hemoglobin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
            "measure": "HbA1C :Glycated Hemoglobin", 
            "safety_issue": "Yes", 
            "time_frame": "84days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724645"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chonbuk National University Hospital", 
            "investigator_full_name": "Soo-Wan Chae", 
            "investigator_title": "director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Triglycerides is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "TG :Triglycerides", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Total cholesterol is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "TC :Total cholesterol", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "HDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "HDL-C :High Density Lipoprotein-Cholesterol", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "LDL-C is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "LDL-C : Low Density Lipoprotein-Cholesterol", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Breathing score is measured in study visits to the clinic, week 0(baseline)and week 12.", 
                "measure": "Breathing score", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Valsalva score is measured in study visits to the clinic, week 0(baseline)and week 12.", 
                "measure": "Valsalva score", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Upright score is measured in study visits to the clinic, week 0(baseline) and week 12.", 
                "measure": "Upright score", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Apolipoprotein A1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "ApoA1 :Apolipoprotein A1", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Apolipoprotein B is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "ApoB :Apolipoprotein B", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Apolipoprotein E is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "Apo E :Apolipoprotein E", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Free fatty acid is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "Free fatty acid", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Adiponectin is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "Adiponectin", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "PAI-1 is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "PAI-1 :Plasminogen activator inhibitor type 1", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Homocysteine is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "Homocysteine", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Fasting plasma glucose is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "FPG :Fasting plasma glucose", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "DBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "DBP:Diastolic Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "SBP is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "SBP:Systolic Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }, 
            {
                "description": "Heart rate is measured in study visits to the clinic, week 0(baseline), week 4, week 8 and week 12.", 
                "measure": "Heart rate", 
                "safety_issue": "Yes", 
                "time_frame": "84days"
            }
        ], 
        "source": "Chonbuk National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chonbuk National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}